TRX-100

Phase 2Small molecule

TTraws Pharma, Inc.

TRX-100 is one of 18 small molecule programs targeting Influenza. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

TRX-100

TTraws Pharma, Inc.

Phase 2

1 8

COMIRNATY

Pfizer

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Influenza

NCT07371650

Clinical

Trials by Indication[1]

Influenza1 trial

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza

Active, not recruiting·TTraws Pharma, Inc.·Phase 2·NCT07371650·105 enrolled

Efficacy1 trial

A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers

Completed·TTraws Pharma, Inc.·Phase 1·NCT06757738·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TRX-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRX-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRX-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Traws Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTraws Pharma, Inc.

TRX-100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Influenza1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News